You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

CLINICAL TRIALS PROFILE FOR TAPINAROF


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Tapinarof

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03956355 ↗ Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) Completed IQVIA Biotech Phase 3 2019-05-21 This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.
NCT03956355 ↗ Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) Completed Dermavant Sciences GmbH Phase 3 2019-05-21 This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.
NCT03983980 ↗ Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) Completed IQVIA Biotech Phase 3 2019-06-06 This is a randomized double-blind vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.
NCT03983980 ↗ Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) Completed Dermavant Sciences GmbH Phase 3 2019-06-06 This is a randomized double-blind vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.
NCT04042103 ↗ Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis Completed Dermavant Sciences GmbH Phase 2 2019-07-23 This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis.
NCT04053387 ↗ Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003) Completed IQVIA Biotech Phase 3 2019-08-13 This is a long-term, open-label, multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in adults with plaque psoriasis. Subjects in this study completed treatment in 1 of 2 Phase 3 pivotal efficacy and safety studies (Study DMVT-505-3001 or Study DMVT-505-3002). This study will consist of up to 40 weeks of treatment and a 4-week safety follow-up period.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tapinarof

Condition Name

Condition Name for Tapinarof
Intervention Trials
Plaque Psoriasis 5
Atopic Dermatitis 4
Psoriasis 3
ICD10 Code L40.9 for Psoriasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tapinarof
Intervention Trials
Psoriasis 9
Eczema 4
Dermatitis, Atopic 4
Dermatitis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tapinarof

Trials by Country

Trials by Country for Tapinarof
Location Trials
United States 154
Canada 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tapinarof
Location Trials
Florida 10
Texas 9
California 9
Indiana 7
Arkansas 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tapinarof

Clinical Trial Phase

Clinical Trial Phase for Tapinarof
Clinical Trial Phase Trials
Phase 4 3
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tapinarof
Clinical Trial Phase Trials
Recruiting 6
Completed 5
Not yet recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tapinarof

Sponsor Name

Sponsor Name for Tapinarof
Sponsor Trials
Dermavant Sciences GmbH 6
Dermavant Sciences, Inc. 6
IQVIA Biotech 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tapinarof
Sponsor Trials
Industry 15
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.